OGS, Pfizer Extend Proteomics Research Collaboration | GenomeWeb

NEW YORK, Dec 19 - Oxford GlycoSciences has extended a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS announced Tuesday.

The new agreement continues a joint research collaboration the two companies began in April 1998 for another two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.